| pubmed-article:20686965 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20686965 | lifeskim:mentions | umls-concept:C1533585 | lld:lifeskim |
| pubmed-article:20686965 | lifeskim:mentions | umls-concept:C0376613 | lld:lifeskim |
| pubmed-article:20686965 | lifeskim:mentions | umls-concept:C1521991 | lld:lifeskim |
| pubmed-article:20686965 | lifeskim:mentions | umls-concept:C1522673 | lld:lifeskim |
| pubmed-article:20686965 | pubmed:dateCreated | 2010-8-5 | lld:pubmed |
| pubmed-article:20686965 | pubmed:abstractText | The use of gene constructs for DNA immunization offers several potential advantages over other commonly used vaccine approaches: (1) full-length cDNA provides multiple potential class I and class II epitopes, thus bypassing limitations of MHC restriction; (2) bacterial plasmid DNA contains immunogenic unmethylated CpG motifs (immunostimulatory sequences) that may act as a potent immunological adjuvant; and (3) DNA is relatively simple to purify in large quantities. The cDNA encoding the antigen of interest is cloned into a bacterial expression plasmid with a constitutively active promoter and this plasmid is injected into the skin or muscle where it is taken up by professional antigen-presenting cells, particularly dendritic cells, either through direct transfection or cross-priming. One can further enhance or modulate the immune response through co-delivery of DNA encoding cytokines or chemokines, including cytokine-Fc fusion molecules. The latter use molecular techniques to fuse a cytokine to the Fc portion of IgG1, creating a chimeric molecule with functional activity. In the present chapter, we will outline the approach to develop cytokine-Fc fusion genes as molecular adjuvants and will use GM-CSF as an example. | lld:pubmed |
| pubmed-article:20686965 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20686965 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20686965 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20686965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20686965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20686965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20686965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20686965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20686965 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20686965 | pubmed:issn | 1940-6029 | lld:pubmed |
| pubmed-article:20686965 | pubmed:author | pubmed-author:PeralesMiguel... | lld:pubmed |
| pubmed-article:20686965 | pubmed:author | pubmed-author:Hirschhorn-Cy... | lld:pubmed |
| pubmed-article:20686965 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20686965 | pubmed:volume | 651 | lld:pubmed |
| pubmed-article:20686965 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20686965 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20686965 | pubmed:pagination | 131-55 | lld:pubmed |
| pubmed-article:20686965 | pubmed:meshHeading | pubmed-meshheading:20686965... | lld:pubmed |
| pubmed-article:20686965 | pubmed:meshHeading | pubmed-meshheading:20686965... | lld:pubmed |
| pubmed-article:20686965 | pubmed:meshHeading | pubmed-meshheading:20686965... | lld:pubmed |
| pubmed-article:20686965 | pubmed:meshHeading | pubmed-meshheading:20686965... | lld:pubmed |
| pubmed-article:20686965 | pubmed:meshHeading | pubmed-meshheading:20686965... | lld:pubmed |
| pubmed-article:20686965 | pubmed:meshHeading | pubmed-meshheading:20686965... | lld:pubmed |
| pubmed-article:20686965 | pubmed:meshHeading | pubmed-meshheading:20686965... | lld:pubmed |
| pubmed-article:20686965 | pubmed:meshHeading | pubmed-meshheading:20686965... | lld:pubmed |
| pubmed-article:20686965 | pubmed:meshHeading | pubmed-meshheading:20686965... | lld:pubmed |
| pubmed-article:20686965 | pubmed:meshHeading | pubmed-meshheading:20686965... | lld:pubmed |
| pubmed-article:20686965 | pubmed:meshHeading | pubmed-meshheading:20686965... | lld:pubmed |
| pubmed-article:20686965 | pubmed:meshHeading | pubmed-meshheading:20686965... | lld:pubmed |
| pubmed-article:20686965 | pubmed:meshHeading | pubmed-meshheading:20686965... | lld:pubmed |
| pubmed-article:20686965 | pubmed:meshHeading | pubmed-meshheading:20686965... | lld:pubmed |
| pubmed-article:20686965 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20686965 | pubmed:articleTitle | Cytokine-FC fusion genes as molecular adjuvants for DNA vaccines. | lld:pubmed |
| pubmed-article:20686965 | pubmed:affiliation | Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USA. | lld:pubmed |
| pubmed-article:20686965 | pubmed:publicationType | Journal Article | lld:pubmed |
